In clinical studies, 10-15% of patients (pts) treated with anti-PD-1 monotherapies achieved durable CRs. Combination treatment with NIVOþIPI resulted in higher response rates, longer progression-free survival (PFS), and improved overall survival (OS) vs IPI alone, but with an increased frequency of adverse events (AEs). Here, we characterized CRs among pts who received combination therapy vs NIVO or IPI alone. Methods: In this post hoc analysis, efficacy and safety data were pooled for NIVOþIPI (N ¼ 409), NIVO (N ¼ 526), and IPI (N ¼ 362) from the phase 2 CheckMate 069, phase 3 CheckMate 066, and phase 3 CheckMate 067 studies in pts with MEL. Across studies, the minimum duration of follow-up was 24 months (median $31 months). Results: In the pooled analysis, the CR rate was 18% for NIVOþIPI, 16% for NIVO, and 4% for IPI, with partial responses (PRs) in 41%, 28%, and 14% of pts, respectively (Table) . Among the 75 CR pts in the NIVOþIPI cohort, the majority (77%) are off treatment and 8% received a subsequent systemic therapy; 15% had elevated LDH levels and 32% had M1c disease. Median duration of CR has not been reached, with 63/75 pts (84%) remaining in response. After an additional follow-up of 12 months (from the 1-year initial follow-up), 24/166 pts (14%) with a PR converted to a CR. For the 75 CR pts in the NIVOþIPI cohort, 2-year PFS and OS rates were 86% and 92%, respectively. Treatment-related AEs of grade 3-4 occurred in 60% of NIVOþIPI-treated pts with a CR, 65% with a PR, and in 60% with stable disease; 31%, 36%, and 35%, respectively, led to discontinuation. There were no treatment-related deaths.
